Literature DB >> 17679461

Liver resection for hepatocellular carcinoma: a multivariate analysis of factors associated with improved prognosis. The role of clinical, pathological and surgical related factors.

Enrico Benzoni1, Dario Lorenzin, Alessandro Favero, Gianluigi Adani, Umberto Baccarani, Roberta Molaro, Aron Zompicchiatti, Enrico Saccomano, Claudio Avellini, Fabrizio Bresadola, Alessandro Uzzau.   

Abstract

AIMS AND
BACKGROUND: Hepatocellular carcinoma (Hcc) is the third most common cause of cancer death. The aim of this study is to examine the factors associated with improved prognosis in Hcc after liver resection. PATIENTS AND METHODS: From September 1989 to March 2005, 134 consecutive patients had liver resection for Hcc on cirrhosis at our department. We performed 54 major liver resections and 80 limited resections. All patients enrolled in the study were followed-up three times during the first year after resection and twice the next years.
RESULTS: In-hospital mortality rate was 7.4%, about 50% of these cases were Child-Pugh B patients. Morbidity rate was 47.7%, caused by the rising of ascites, temporary liver impairment function, biliary fistula, hepatic abscess, hemoperitoneum and pleural effusion. Overall survival resulted to be influenced by etiology (P = 0.03), underlying liver disease, in particular Child A vs BC (P = 0.04), Endmondson-Steiner grading (P = 0.01), the absence of a capsule (P = 0.004), the presence of more than one lesion (P = 0.02), lesion's size over 5 cm (P = 0.04), Pringle maneuver length over than 20 minutes (P = 0.03), an amount of resected liver volume lesser than 50% of total liver volume (P = 0.03), and the relapse of Hcc (P= 0.01).
CONCLUSIONS: The treatment of hepatocellular carcinoma should be both the most radical to obtain the best outcome and to reduce the recurrence's rate, and the most suitable according to the patient's condition, lesion's characteristics and underlying liver disease: because of the large number of factors affecting the outcome of Hcc, unfortunately, we are still far from an agreement upon a group of criteria useful to select the best candidates for liver resection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17679461     DOI: 10.1177/030089160709300306

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  9 in total

Review 1.  Management of post-hepatectomy complications.

Authors:  Shan Jin; Quan Fu; Gerile Wuyun; Tu Wuyun
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

3.  Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre.

Authors:  T Asmis; F Balaa; L Scully; D Papadatos; C Marginean; N Fasih; T Shaw-Stiffel; R Goel
Journal:  Curr Oncol       Date:  2010-04       Impact factor: 3.677

4.  Shock releases bile acid inducing platelet inhibition and fibrinolysis.

Authors:  Gregory Wiener; Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Scott Diamond; Shu Zhu; Angelo D'Alessandro; Anirban Banerjee
Journal:  J Surg Res       Date:  2015-01-29       Impact factor: 2.192

5.  Operation start time and long-term outcome of hepatocellular carcinoma after curative hepatic resection.

Authors:  Qiang Lu; Qing-Shan Li; Wei Zhang; Kang Liu; Tao Li; Jia-Wei Yu; Yi Lv; Xu-Feng Zhang
Journal:  Ann Surg Treat Res       Date:  2020-06-29       Impact factor: 1.859

6.  Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.

Authors:  Michelle Z Xu; Tzy-Jyun Yao; Nikki P Y Lee; Irene O L Ng; Yuk-Tat Chan; Lars Zender; Scott W Lowe; Ronnie T P Poon; John M Luk
Journal:  Cancer       Date:  2009-10-01       Impact factor: 6.860

7.  Clinicopathologic and gene expression parameters predict liver cancer prognosis.

Authors:  Ke Hao; John Lamb; Chunsheng Zhang; Tao Xie; Kai Wang; Bin Zhang; Eugene Chudin; Nikki P Lee; Mao Mao; Hua Zhong; Danielle Greenawalt; Mark D Ferguson; Irene O Ng; Pak C Sham; Ronnie T Poon; Cliona Molony; Eric E Schadt; Hongyue Dai; John M Luk
Journal:  BMC Cancer       Date:  2011-11-09       Impact factor: 4.430

Review 8.  Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges.

Authors:  Jonathan Michael Harnoss; Moritz Johannes Strowitzki; Praveen Radhakrishnan; Lisa Katharina Platzer; Julian Camill Harnoss; Thomas Hank; Jun Cai; Alexis Ulrich; Martin Schneider
Journal:  Hypoxia (Auckl)       Date:  2015-01-30

9.  Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters.

Authors:  Ke Hao; John M Luk; Nikki P Y Lee; Mao Mao; Chunsheng Zhang; Mark D Ferguson; John Lamb; Hongyue Dai; Irene O Ng; Pak C Sham; Ronnie T P Poon
Journal:  BMC Cancer       Date:  2009-11-03       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.